文献速递老年综合评估老年慢病共病管理

新型多病共存指数的开发与验证:针对老年人的索赔数据测量

Development and validation of novel multimorbidity indices for older adults.
PubMed 文献 · J Am Geriatr Soc · 2022-10-25

本研究利用健康与退休研究中67岁及以上参保人的医疗保险索赔数据,开发了针对ADL下降、IADL下降、住院和死亡四个结局的多病共存指数,并在国家健康与老龄化趋势研究中验证。新指数在预测功能下降和住院方面略优于Charlson和Elixhauser指数,但对死亡预测无改善,决策曲线分析显示临床净获益有限。

要点

  • 新指数对ADL下降、IADL下降、住院的c统计量分别为0.72、0.69、0.72,略高于传统指数。
  • 对死亡预测的c统计量为0.77,与传统指数差异小于0.01且无统计学意义。
  • 决策曲线分析显示新指数相比传统方法仅带来极小临床净获益。

核心结论

  • 基于索赔数据的新型多病共存指数在预测住院和功能下降方面略优于Charlson和Elixhauser指数,但对死亡预测无改善。
  • 索赔数据中改进多病共存测量的空间可能有限。

研究设计与样本

  • 利用健康与退休研究中67岁及以上受试者的医疗保险住院和门诊索赔数据开发指数,开发队列5012人,中位年龄76岁,58%为女性。
  • 分别针对2年随访内的ADL下降、IADL下降、住院和死亡开发独立指数,并在与国家健康与老龄化趋势研究链接的医疗保险索赔数据中验证。

主要发现

  • 基于索赔的疾病严重度标志物和疾病-疾病交互作用带来的预测效能增益极小,未纳入最终指数。
  • 验证队列中调整年龄和性别后,新指数c统计量:ADL下降0.72,IADL下降0.69,住院0.72,死亡0.77。
  • 新指数c统计量较Charlson和Elixhauser指数在ADL下降、IADL下降和住院预测上高0.02-0.03,死亡预测高小于0.01(除死亡外各结局p<0.05)。
  • 新指数与CMS-HCC模型表现相似。
  • 决策曲线分析显示新指数相比传统方法仅带来极小获益。

关键数值与推荐

  • 开发队列样本量5012人,中位年龄76岁,女性占58%。
  • 验证队列c统计量:ADL下降0.72,IADL下降0.69,住院0.72,死亡0.77。
  • 新指数c统计量较Charlson和Elixhauser指数提高0.02-0.03(ADL下降、IADL下降、住院)和小于0.01(死亡),除死亡外p<0.05。

临床怎么用

  • 在老年医学临床风险评估中,可考虑使用针对特定结局定制的索赔数据多病共存指数,但其相较于传统指数的增量价值有限。
  • 不应期望索赔数据多病共存指数能显著改善死亡风险预测。

局限性

  • 基于索赔的疾病严重度标志物和疾病-疾病交互作用未显著提升预测效能。
  • 新指数和传统指数的c统计量在推导队列和验证队列间存在较大差异。
  • 决策曲线分析显示新指数相比传统方法仅带来极小临床净获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Measuring multimorbidity in claims data is used for risk adjustment and identifying populations at high risk for adverse events. Multimorbidity indices such as Charlson and Elixhauser scores have important limitations. We sought to create a better method of measuring multimorbidity using claims data by incorporating geriatric conditions, markers of disease severity, and disease-disease interactions, and by tailoring measures to different outcomes. METHODS: Health conditions were assessed using Medicare inpatient and outpatient claims from subjects age 67 and older in the Health and Retirement Study. Separate indices were developed for ADL decline, IADL decline, hospitalization, and death, each over 2 years of follow-up. We validated these indices using data from Medicare claims linked to the National Health and Aging Trends Study. RESULTS: The development cohort included 5012 subjects with median age 76 years; 58% were female. Claims-based markers of disease severity and disease-disease interactions yielded minimal gains in predictive power and were not included in the final indices. In the validation cohort, after adjusting for age and sex, c-statistics for the new multimorbidity indices were 0.72 for ADL decline, 0.69 for IADL decline, 0.72 for hospitalization, and 0.77 for death. These c-statistics were 0.02-0.03 higher than c-statistics from Charlson and Elixhauser indices for predicting ADL decline, IADL decline, and hospitalization, and <0.01 higher for death (p < 0.05 for each outcome except death), and were similar to those from the CMS-HCC model. On decision curve analysis, the new indices provided minimal benefit compared with legacy approaches. C-statistics for both new and legacy indices varied substantially across derivation and validation cohorts. CONCLUSIONS: A new series of claims-based multimorbidity measures were modestly better at predicting hospitalization and functional decline than several legacy indices, and no better at predicting death. There may be limited opportunity in claims data to measure multimorbidity better than older methods.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Steinman MA, Jing B, Shah SJ, et al. Development and validation of novel multimorbidity indices for older adults. J Am Geriatr Soc. 2022. PMID: 36282202. doi:10.1111/jgs.18052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。